1. Home
  2. PED vs NXTC Comparison

PED vs NXTC Comparison

Compare PED & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pedevco Corp.

PED

Pedevco Corp.

HOLD

Current Price

$0.56

Market Cap

53.5M

Sector

Energy

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

N/A

Current Price

$13.27

Market Cap

46.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PED
NXTC
Founded
N/A
2015
Country
United States
United States
Employees
14
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
53.5M
46.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PED
NXTC
Price
$0.56
$13.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$1.50
$23.00
AVG Volume (30 Days)
148.8K
38.8K
Earning Date
11-17-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
156.43
N/A
EPS
0.11
N/A
Revenue
$33,244,999.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$305.89
N/A
P/E Ratio
$5.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$2.69
52 Week High
$1.00
$15.74

Technical Indicators

Market Signals
Indicator
PED
NXTC
Relative Strength Index (RSI) 51.74 56.64
Support Level $0.55 $12.99
Resistance Level $0.60 $14.65
Average True Range (ATR) 0.03 1.00
MACD 0.00 0.04
Stochastic Oscillator 57.90 64.24

Price Performance

Historical Comparison
PED
NXTC

About PED Pedevco Corp.

PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: